By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
blog.sciencebriefing.com
  • Medicine
  • Biology
  • Engineering
  • Environment
  • More
    • Chemistry
    • Physics
    • Agriculture
    • Business
    • Computer Science
    • Energy
    • Materials Science
    • Mathematics
    • Politics
    • Social Sciences
Notification
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Personalize
blog.sciencebriefing.comblog.sciencebriefing.com
Font ResizerAa
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Search
  • Quick Access
    • Home
    • Contact Us
    • Blog Index
    • History
    • My Saves
    • My Interests
    • My Feed
  • Categories
    • Business
    • Politics
    • Medicine
    • Biology

Top Stories

Explore the latest updated news!

A million LEDs, and a new way to write on cortex

Two dopamine “votes” in the amygdala that steer exploration

The brain’s feeding decisions, broken into moving parts

Stay Connected

Find us on socials
248.1KFollowersLike
61.1KFollowersFollow
165KSubscribersSubscribe
Made by ThemeRuby using the Foxiz theme. Powered by WordPress

Home - Oncology - Copper’s Double-Edged Sword: A New Frontier in Cancer Therapy and Nanomedicine

Oncology

Copper’s Double-Edged Sword: A New Frontier in Cancer Therapy and Nanomedicine

Last updated: February 10, 2026 1:57 am
By
Science Briefing
ByScience Briefing
Science Communicator
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Follow:
No Comments
Share
SHARE

Copper’s Double-Edged Sword: A New Frontier in Cancer Therapy and Nanomedicine

A comprehensive review in *Molecular Pharmaceutics* explores the intricate role of copper in cancer biology, from its essential homeostatic functions to its potential as a lethal weapon. The article details how dysregulated copper metabolism is a hallmark of tumorigenesis, supporting angiogenesis, metastasis, and oncogenic signaling pathways. Crucially, it deciphers the emerging concept of “cuproptosis”—a novel form of regulated cell death triggered by copper overload, distinct from apoptosis. The review then connects these biological mechanisms to cutting-edge therapeutic strategies, focusing on the design of copper-based nanomedicines that can exploit cancer-specific vulnerabilities for targeted therapy.

Why it might matter to you: This research directly addresses the core challenge of drug resistance by outlining a novel cell death pathway that could bypass traditional apoptotic defects common in tumors. For professionals focused on precision oncology, understanding cuproptosis opens avenues for new biomarker development and combination therapies. The focus on nanomedicine translates fundamental cancer biology into actionable therapeutic platforms, highlighting a strategic shift towards leveraging intrinsic tumor metabolism for next-generation targeted interventions.

Source →

Stay curious. Stay informed — with Science Briefing.

Always double check the original article for accuracy.

- Advertisement -

Feedback

Share This Article
Facebook Flipboard Pinterest Whatsapp Whatsapp LinkedIn Tumblr Reddit Telegram Threads Bluesky Email Copy Link Print
Share
ByScience Briefing
Science Communicator
Follow:
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Previous Article How a new predator reshapes an old fish: rapid evolution in action
Next Article A New Frontier in Emergency Care: The Silent Screening for Heart Risks
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related Stories

Uncover the stories that related to the post!

A New Dual-Targeted ADC Shows Promise in Resistant EGFR-Mutant Lung Cancer

A New Blueprint for Measuring Success in Neoadjuvant Immunotherapy

A New Window into Tumor Microenvironment and Therapeutic Delivery

A New Guideline for Personalizing Cancer Drug Dosing

A New Model for Precision Dosing in Metastatic Breast Cancer

Heart Failure, Diabetes, and a Drug’s Interplay in Non-Oncology Patients

Machine Learning Uncovers a Metabolic Signature Linked to Cancer Risk

A New Target Emerges: How Platelet Channels Fuel Thrombosis in a Cancer-Linked Syndrome

Show More

Science Briefing delivers personalized, reliable summaries of new scientific papers—tailored to your field and interests—so you can stay informed without doing the heavy reading.

blog.sciencebriefing.com
  • Categories:
  • Medicine
  • Biology
  • Social Sciences
  • Chemistry
  • Engineering
  • Cell Biology
  • Gastroenterology
  • Genetics
  • Energy
  • Microbiology

Quick Links

  • My Feed
  • My Interests
  • History
  • My Saves

About US

  • Adverts
  • Our Jobs
  • Term of Use

ScienceBriefing.com, All rights reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?